anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: SODIUM CHLORIDE
Trial phase: Phase 1 | Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: Female
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 12
Group description: Saline administered by trans-cervical infusion one time on day of hCG trigger for ovulation
Eligibility criteria:
Inclusion Criteria:

Patient's preparing for invitro fertilization and embryo transfer with endometrial growth of less than 7 mm, unresponsive to standard treatment

Exclusion Criteria:

Sickle Cell disease
Renal insufficiency
Upper respiratory infection or Pneumonia
Chronic Neutropenia
Known Past or present malignancy
Intervention: Atenolol
Trial phase: Phase 3
ATC code: C07AB03 | C07BB03 | C07CB03 | C07CB53 | C07DB01 | C07FB03
SMILES: CC(C)NCC(O)COc1ccc(CC(N)=O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: Atenolol 25 mg up-titrated to 100 mg.
Eligibility criteria:
Inclusion Criteria:

Age => 18 years
Men and women with BAV and ascending aorta measuring > 37mm.
Written informed consent

General Study Exclusion Criteria

History of cardiac diseases, such as

Symptomatic aortic stenosis or aortic regurgitation referred for surgical intervention or asymptomatic severe aortic stenosis or regurgitation based on current guidelines
Uncontrolled heart failure, right ventricular failure due to pulmonary hypertension
Cardiogenic shock
Systolic blood pressure < 100 mmHg
History of drug sensitivity, contraindication or adverse reaction to both BB and ARB. Participants who are able to tolerate only a BB will be allocated to the BB vs. placebo arm, and participants who are able to tolerate only an ARB will be allocated to the ARB vs. placebo arm, assuming no other exclusion criteria are met.
Ascending aorta measuring ≥ 50mm, requiring prophylactic ascending aorta surgery
Unable to provide informed consent
Need for both BB and ARB for treatment of concomitant medical conditions for which there are no other alternatives. Participants who are taking an ARB which cannot be discontinued will be allocated to the BB arm, and participants who are taking a BB which cannot be discontinued will be allocated to the ARB arm, if no other exclusion criteria are met.
Prior surgery on ascending aorta or aortic root (balloon valvuloplasty, aortic valvotomy or post coarctation surgery are acceptable)
Women who are pregnant at screening visit
Contraindication to MRI (claustrophobia, pacemaker, metallic clip in eye or brain)
History of any illness which limits the participants' ability to complete the study

Additional Exclusion Criteria for BB arm only

Heart rate <60 bpm
Heart block (1st, 2nd and 3rd degree AV block on ECG), or sick sinus syndrome
Asthma of sufficient severity to represent a contraindication to BB use in the judgment of the patient's physician
History of severe peripheral artery disorders
History of pheochromocytoma without the use of alpha-adrenergic blockers
History of metabolic acidosis

Additional Exclusion Criteria for ARB arm only

Women who are pregnant, lactating or who intend to become pregnant during the course of the study
Women who are of childbearing age and are not on reliable, accepted form of birth control
Hyperkalemia [serum potassium > 5.5 mmol/L] or renal dysfunction [GFR<45% measured by MDRD)
Patients being treated with an ACE Inhibitor that cannot be discontinued. (These patients may be randomized in the BB arm if no exclusion criteria are met.)
History of bilateral renal artery stenosis or unilateral renal artery stenosis to a solitary kidney
History of hepatic insufficiency and hepato-biliary obstruction
History of fructose intolerance
Intervention: Ertapenem
Trial phase: Phase 2 | Phase 3
ATC code: J01DH03
SMILES: [H][C@@]1(SC2=C(C(=O)O)N3C(=O)[C@]([H])([C@@H](C)O)[C@@]3([H])[C@H]2C)CN[C@]([H])(C(=O)Nc2cccc(C(=O)O)c2)C1
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 56
Group description: Ertapenem will be administrated within the first 2 hours of Hospital´s admission and the next two days after surgery. At day four, patients will be assigned to different groups A or B, according to they entrance number into this trial.

Group A will be treated with Ertapenem during the following four days.
Eligibility criteria:
Inclusion Criteria:

Patients with penetrating abdominal trauma who attended the emergency room within 12 hours after trauma, admitted to an exploratory laparotomy.
Patients aged 12 to 65 years.

Exclusion Criteria:

Clinical history of immunologic diseases, cancer, use of immunosuppressors, steroids, malnutrition, morbid obesity.
Concomitant pathology at admittance: urinary infections, respiratory infections, hepatitis, viral diseases.
Associated open bone fractures.
Patients with hemodynamic instability during pre or peroperative.
Intervention: Edoxaban
Trial phase: Phase 2
ATC code: B01AF03
SMILES: CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 103
Group description: DU-176b: DU-176b 5mg tablets oral, once daily for 2 weeks
Eligibility criteria:
Inclusion Criteria:

Patients undergoing unilateral total knee arthroplasty

Exclusion Criteria:

risks of hemorrhage
thromboembolic risks
weight less than 40 kg
pregnant, suspect pregnancy, or subjects who want to become pregnant
Intervention: Edoxaban
Trial phase: Phase 2
ATC code: B01AF03
SMILES: CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 106
Group description: DU-176b: DU-176b 15mg tablets, oral once daily for 2 weeks
Eligibility criteria:
Inclusion Criteria:

Patients undergoing unilateral total knee arthroplasty

Exclusion Criteria:

risks of hemorrhage
thromboembolic risks
weight less than 40 kg
pregnant, suspect pregnancy, or subjects who want to become pregnant
Intervention: Edoxaban
Trial phase: Phase 2
ATC code: B01AF03
SMILES: CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 103
Group description: DU-176b: DU-176b 30 mg tablets, oral, once daily for 2 weeks
Eligibility criteria:
Inclusion Criteria:

Patients undergoing unilateral total knee arthroplasty

Exclusion Criteria:

risks of hemorrhage
thromboembolic risks
weight less than 40 kg
pregnant, suspect pregnancy, or subjects who want to become pregnant
Intervention: Edoxaban
Trial phase: Phase 2
ATC code: B01AF03
SMILES: CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 106
Group description: DU-176b: DU-176b 60 mg tablets, oral, once daily for 2 weeks
Eligibility criteria:
Inclusion Criteria:

Patients undergoing unilateral total knee arthroplasty

Exclusion Criteria:

risks of hemorrhage
thromboembolic risks
weight less than 40 kg
pregnant, suspect pregnancy, or subjects who want to become pregnant
Intervention: Bupivacaine hydrochloride
Trial phase: Phase 2
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C.Cl
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Low dose, low-mid dose, mid-dose, and high dose
Eligibility criteria:
Inclusion Criteria:

Males ≥18 years of age at the Screening visit.
Scheduled to undergo unilateral inguinal hernia repair under general anesthesia, using an open, tension free procedure (e.g., Lichtenstein technique with or without mesh).
American Society of Anesthesiology (ASA) Physical Class 1 or 2.
Able and willing to comply with all study visits and procedures.
Capable of speaking and understanding the local language sufficiently to provide responses to pain assessment scales.
Willing and capable of providing written informed consent.

Exclusion Criteria:

Clinically significant electrocardiogram abnormalities at Screening or on Day 1 (pre administration).
Albumin and/or alpha 1 acid glycoprotein (AAG) below normal levels.
Current or historical evidence of any clinically significant disease or condition that, in the opinion of the Investigator, might have increased the risk of surgery or complicated the subject's postoperative course.
Opioid medication usage during the 7 day period preceding the administration of study drug.
Current medical conditions that could have required treatment with analgesic medications in the postoperative period for pain that was not surgically related (e.g., rheumatoid arthritis).
Body mass index >30 kg/m^2
Body weight <60 kg.
History of hypersensitivity or idiosyncratic reaction to amide type local anesthetic agents.
History of hypersensitivity, idiosyncratic reactions, and other contraindications to the pain control agents (opioid or non-opioid) anticipated to be used postoperatively. These contraindications may have included: angioedema and bronchospastic reactivity to non steroidal anti inflammatory drug, peptic ulcer (active within the last three months), hepatic or renal insufficiency.
Coagulation disorders or ongoing anticoagulation treatment.
Administration of an investigational drug within 30 days or five half lives (of elimination), whichever was longer, prior to study drug administration.
Suspected or known history of substance abuse and/or alcoholism.
Clinically significant complications during the hernia repair surgery (e.g., excessive bleeding), which might have rendered the subject medically unstable or might have complicated the subject's postoperative course.
Intervention: Linagliptin
Trial phase: Phase 3
ATC code: A10BD11 | A10BD19 | A10BD27 | A10BH05
SMILES: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 82
Group description: biguanide plus linagliptin
Eligibility criteria:
Inclusion criteria:

Diagnosis of type 2 diabetes mellitus
Male and female patients on diet and exercise regimen who are treated with one antidiabetic drug

Exclusion criteria:

Myocardial infarction, stroke, transient ischemic attack, or pulmonary embolism
Impaired hepatic function
Glitazone, glinide, and sulfonylurea group: renal failure or renal impairment defined as estimated glomerular filtration rate <30 ml/min (severe renal impairment) at Visit 1, Biguanide group: renal failure or renal impairment defined as estimated glomerular filtration rate <60 ml/min (moderate renal impairment) at Visit 1
Treatment with anti-obesity drugs
Intervention: Linagliptin
Trial phase: Phase 3
ATC code: A10BD11 | A10BD19 | A10BD27 | A10BH05
SMILES: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 66
Group description: glinide plus linagliptin
Eligibility criteria:
Inclusion criteria:

Diagnosis of type 2 diabetes mellitus
Male and female patients on diet and exercise regimen who are treated with one antidiabetic drug

Exclusion criteria:

Myocardial infarction, stroke, transient ischemic attack, or pulmonary embolism
Impaired hepatic function
Glitazone, glinide, and sulfonylurea group: renal failure or renal impairment defined as estimated glomerular filtration rate <30 ml/min (severe renal impairment) at Visit 1, Biguanide group: renal failure or renal impairment defined as estimated glomerular filtration rate <60 ml/min (moderate renal impairment) at Visit 1
Treatment with anti-obesity drugs
Intervention: Linagliptin
Trial phase: Phase 3
ATC code: A10BD11 | A10BD19 | A10BD27 | A10BH05
SMILES: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 74
Group description: glitazone plus linagliptin
Eligibility criteria:
Inclusion criteria:

Diagnosis of type 2 diabetes mellitus
Male and female patients on diet and exercise regimen who are treated with one antidiabetic drug

Exclusion criteria:

Myocardial infarction, stroke, transient ischemic attack, or pulmonary embolism
Impaired hepatic function
Glitazone, glinide, and sulfonylurea group: renal failure or renal impairment defined as estimated glomerular filtration rate <30 ml/min (severe renal impairment) at Visit 1, Biguanide group: renal failure or renal impairment defined as estimated glomerular filtration rate <60 ml/min (moderate renal impairment) at Visit 1
Treatment with anti-obesity drugs
Intervention: Linagliptin
Trial phase: Phase 3
ATC code: A10BD11 | A10BD19 | A10BD27 | A10BH05
SMILES: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 143
Group description: sulfonylurea plus linagliptin
Eligibility criteria:
Inclusion criteria:

Diagnosis of type 2 diabetes mellitus
Male and female patients on diet and exercise regimen who are treated with one antidiabetic drug

Exclusion criteria:

Myocardial infarction, stroke, transient ischemic attack, or pulmonary embolism
Impaired hepatic function
Glitazone, glinide, and sulfonylurea group: renal failure or renal impairment defined as estimated glomerular filtration rate <30 ml/min (severe renal impairment) at Visit 1, Biguanide group: renal failure or renal impairment defined as estimated glomerular filtration rate <60 ml/min (moderate renal impairment) at Visit 1
Treatment with anti-obesity drugs
Intervention: Linagliptin
Trial phase: Phase 3
ATC code: A10BD11 | A10BD19 | A10BD27 | A10BH05
SMILES: CC#CCn1c(N2CCC[C@@H](N)C2)nc2c1c(=O)n(Cc1nc(C)c3ccccc3n1)c(=O)n2C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 85
Group description: alpha-glucosidase inhibitor plus linagliptin
Eligibility criteria:
Inclusion criteria:

Diagnosis of type 2 diabetes mellitus
Male and female patients on diet and exercise regimen who are treated with one antidiabetic drug

Exclusion criteria:

Myocardial infarction, stroke, transient ischemic attack, or pulmonary embolism
Impaired hepatic function
Glitazone, glinide, and sulfonylurea group: renal failure or renal impairment defined as estimated glomerular filtration rate <30 ml/min (severe renal impairment) at Visit 1, Biguanide group: renal failure or renal impairment defined as estimated glomerular filtration rate <60 ml/min (moderate renal impairment) at Visit 1
Treatment with anti-obesity drugs
Intervention: Procainamide
Trial phase: Not Applicable
ATC code: C01BA02
SMILES: CCN(CC)CCNC(=O)c1ccc(N)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 106
Group description: Those patients with ST segment or J Point elevation on electrocardiogram. Can be on initial screening electrocardiogram or on electrocardiograms during procainamide infusion. These subjects will also have SCN5A mutation.

Procainamide: One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
Eligibility criteria:
Inclusion Criteria:

18 years of age or older
Undergoing AF ablation at Vanderbilt or MGH

Exclusion Criteria:

Patients taking membrane active anti-arrhythmic drugs with sodium channel blocking properties (amiodarone, dronedarone, flecainide, propafenone) at the time of the ablation
Patients with a history of Brugada syndrome or type 1 Brugada ECG pattern on the baseline ECG
Patients with a history of drug-induced torsades de pointes
Patients with a known history of hypersensitivity to procainamide, procaine or related drugs
Patients with a history of systemic lupus erythematosus and myasthenia gravis
Patients with a history of second degree AV block (Mobitz type II) or third degree AV block
Women of child-bearing potential unless post-menopausal, surgically sterile, or have a negative pregnancy test day on the day of procedure
Patients with dual chamber pacemakers or implantable defibrillators requiring ventricular pacing (uninterpretable ECG)
Patients unable to give informed consent
Intervention: Victoza
Trial phase: Phase 2
ATC code: A10BJ02
SMILES: CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1ccccc1)C(=O)NC(C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Liraglutide was injected subcutaneously once-daily. The dose of liraglutide was escalated up to 1.8 mg (or 1.2 mg if 1.8 mg not tolerated) prior to islet cell transplant and continued until one year after the first transplant in each subject.
Eligibility criteria:
Inclusion Criteria:

Type 1 diabetes mellitus for at least 5 years
Candidate for islet cell transplantation based upon local accepted practice and guidelines
Reduced awareness of hypoglycaemia

Exclusion Criteria:

Treatment with any anti-diabetic medication other than insulin including insulin pump within 4 weeks of trial start
Any previous organ transplantation
A history of acute idiopathic or chronic pancreatitis
Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
Intervention: Desoximetasone
Trial phase: Phase 3
ATC code: D07AC03 | D07XC02
SMILES: [H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1(F)[C@@H](O)C[C@]1(C)[C@@H](C(=O)CO)[C@H](C)C[C@@]21[H]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 60
Group description: Desoximetasone Spray 0.25%: Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
Eligibility criteria:
Inclusion Criteria:

Male or non-pregnant, non-lactating female 18 years of age or older.
Have a definite clinical diagnosis of stable plaque psoriasis involving ≥ 10% of the body surface area (BSA).
Have a combined total lesion severity score (TLSS) of ≥ 7 for the Target Lesion.
Have a plaque elevation score ≥ 3 of (moderate) for the Target Lesion.
The Target Lesion must have an area of at least 5 cm².
Have a Physicians Global Assessment (PGA) score of 3 (moderate) or 4 (severe) at baseline for the overall disease severity.

Exclusion Criteria:

Patient has current diagnosis of other types of psoriasis other than stable plaque psoriasis (i.e. acute, guttate, erythrodermic, exfoliative or pustular psoriasis) or has psoriasis of any kind of the face or scalp that will require active treatment during the study. Nonprescription antipsoriatic shampoos will be allowed during the study when applied solely to the scalp.
Patient has a history of psoriasis that has been unresponsive to topical corticosteroid therapy.
In the Investigator's opinion, the patient has other dermatological conditions, such as atopic or contact dermatitis, that may interfere with the clinical assessments of the signs and symptoms of psoriasis.
Patient has a history of allergy or sensitivity to corticosteroids or history of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the patient or the results of the study.
Patient has been treated within 12 weeks (or five half lives, whichever is less) prior to the first dose of study drug with any biological therapies for psoriasis.
Patient has received any systemic steroids within 4 weeks of the first dose of the study drug. The use of inhaled or intranasal corticosteroids is acceptable as long as usage has been stable for at least 2 weeks prior to the first dose of study drug and will be continued during the study.
Patients who have used any topical antipsoriatic agents of any kind or any topical corticosteroids for any reason within 2 weeks prior to first use of study drug. Nonprescription antipsoriatic shampoos used only on the scalp will be allowed during the study.
Receipt of any drug as part of a research study within 30 days prior to first dosing.
Intervention: Nebivolol
Trial phase: Phase 4
ATC code: C07AB12 | C07BB12 | C07FB12 | C09DX05
SMILES: OC(CNCC(O)C1CCc2cc(F)ccc2O1)C1CCc2cc(F)ccc2O1
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 2
Group description: Subject will receive either 5 or 10 mg of oral nebivolol daily. Dose will be determined by control of blood pressure.

nebivolol: nebivolol 5 or 10 mg oral, daily
Eligibility criteria:
Inclusion Criteria:

Diagnosis of hypertension
Written informed consent before initiation of any study related procedure
Baseline Blood pressure > 140 systolic or >90 diastolic if on no antihypertensive therapy.
Currently taking one antihypertensive or one antihypertensive and one diuretic for the treatment of hypertension.

Exclusion Criteria:

Physical limitations resulting in a limited ability to walk on treadmill for stress echo
Intolerance to beta blockers
On more than one medication for the treatment of hypertension unless the second medication is a diuretic.
Currently pregnant or breast feeding.
LFT > 3 X ULN
HgA1C > 7
Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within past 30 days of enrollment
Unwilling to follow protocol or return for study related procedures.

Any of the following conditions:

Coronary artery disease Heart failure Valvular heart disease Ischemic heart disease Atrial fibrillation Pacemaker ICD Hyperlipidemia Diabetes Mellitus Stroke/TIA Anemia COPD Asthma Renal failure requiring dialysis Liver failure Cirrhosis Thyroid dysfunction

Any other medical condition that in the PI's opinion could affect myocardial function.
Current ETOH or illicit drug abuse -
Intervention: Prednisone
Trial phase: Phase 4
ATC code: A07EA03 | H02AB07
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)CC(=O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@@]21C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Participants undergo ablation procedure and receive predinisone at protocol determined times.

Prednisone: 60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure

Ablation Procedure: Atrial Fibrillation (AF) ablation
Eligibility criteria:
Inclusion Criteria:

Able to provide written informed consent;
Scheduled for radiofrequency ablation procedure for treatment of atrial fibrillation

Exclusion Criteria:

History of heart failure (right or left or biventricular) or cardiomyopathy.
Immunosuppressive disorders and systemic fungal infection
Concurrent use of corticosteroids in one week prior recruitment.
Allergy or prednisone or its components.
Other medical conditions were use of corticosteroids is not recommended or contraindicated.
Patients with chronic and permanent atrial fibrillation.
Patients with established diagnosis of rheumatological and immunological disorders.